WallStSmart

Abbott Laboratories (ABT)vsMaxCyte Inc (MXCT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 128689% more annual revenue ($44.33B vs $34.42M). ABT leads profitability with a 14.7% profit margin vs -132.6%. ABT earns a higher WallStSmart Score of 51/100 (C-).

ABT

Buy

51

out of 100

Grade: C-

Growth: 5.3Profit: 6.5Value: 7.3Quality: 4.8
Piotroski: 3/9

MXCT

Avoid

32

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 5.0Quality: 8.0
Piotroski: 2/9Altman Z: 2.75
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-315.5%)

Margin of Safety

-315.5%

Fair Value

$25.23

Current Price

$104.83

$79.60 premium

UndervaluedFair: $25.23Overvalued

Intrinsic value data unavailable for MXCT.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT3 strengths · Avg: 8.3/10
Market CapQuality
$180.82B9/10

Large-cap with strong market position

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$2.63B8/10

Generating 2.6B in free cash flow

MXCT2 strengths · Avg: 9.5/10
Price/BookValuation
0.4x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

ABT4 concerns · Avg: 3.8/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

P/E RatioValuation
28.1x4/10

Moderate valuation

Revenue GrowthGrowth
4.4%4/10

4.4% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

MXCT4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$80.74M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-23.2%2/10

ROE of -23.2% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : MXCT

The strongest argument for MXCT centers on Price/Book, Debt/Equity.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.

Bear Case : MXCT

The primary concerns for MXCT are EPS Growth, Market Cap, Piotroski F-Score.

Key Dynamics to Monitor

ABT profiles as a value stock while MXCT is a turnaround play — different risk/reward profiles.

MXCT carries more volatility with a beta of 1.43 — expect wider price swings.

ABT is growing revenue faster at 4.4% — sustainability is the question.

ABT generates stronger free cash flow (2.6B), providing more financial flexibility.

Bottom Line

ABT scores higher overall (51/100 vs 32/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

MaxCyte Inc

HEALTHCARE · MEDICAL DEVICES · USA

MaxCyte Inc. (MXCT) is a leading innovator in cell-engineering solutions, renowned for its proprietary Flow Electroporation® technology that enables efficient and scalable delivery of nucleic acids and proteins across diverse cell types. Catering to a broad spectrum of clients, including major biopharmaceutical companies and research institutions, MaxCyte plays a critical role in the rapidly evolving cell and gene therapy market. The company's advanced platforms are essential for the development of cutting-edge cell-based therapies and vaccines, positioning MaxCyte to capitalize on significant growth opportunities in the healthcare sector. With a steadfast dedication to advancing transformative treatment options, MaxCyte is well-equipped to address the escalating global demand for innovative therapeutic modalities.

Visit Website →

Want to dig deeper into these stocks?